Menu

Experimental Ebola Vaccine to be Used in DRC Outbreak

As the virus spreads in Democratic Republic of Congo, the World Health Organization is preparing to immunize people as soon as this week.

May 14, 2018
Kerry Grens

Sierra Leone, 2015ISTOCK, HARRY1978The World Health Organization, the government of Democratic Republic of Congo, and Merck have agreed to use Merck’s unapproved Ebola vaccine as an outbreak of the virus expands in DRC.

“The cold chain is on standby, the stockpile is on standby, the teams have been put on standby including up to 40 people that conducted the initial ring vaccination trial in Guinea,” Peter Salama, the World Health Organization’s (WHO) deputy director-general of emergency preparedness and response, said during a United Nations briefing on Friday (May 11), according to Reuters. The Guinea field trial in 2016 found the vaccine to be 100 percent effective at preventing infection among the 6,000 people who received it.

See “Ebola Vaccine Success

So far this spring, 19 people have died of Ebola in DRC. The outbreak is in a remote part of the country, where delivering the vaccine will be a challenge because it must be kept frozen. According to STAT, the cold-chain equipment to keep the vaccine chilled was to arrive in DRC yesterday and the vaccine itself will be shipped from Geneva later this week.

Despite its isolation, the outbreak’s epicenter is just three hours by road to a city of 1 million people, and public health officials are concerned it could spread, The New York Times reports.

See “Two Ebola Cases Confirmed in Democratic Republic of Congo

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.